Transfusion-transmitted infections in haemophilia patients

Bosnian Journal of Basic Medical Sciences

Volumn 9, Issue 4, 2009, Pages 271-277

  Zhubi, Bukurije ^a   Mekaj, Ymer ^a   Baruti, Zana ^b   Bunjaku, Ilirijane ^c   Belegu, Mazllum ^a  

^a National Blood Transfusion Centre of Kosovo Prishtina (NBTCK)   (Greece)

^b UNIVERSITY OF PRISHTINA   (Serbia)

^c Department of Pulmology   (Greece)

Author keywords

Hemophilia A and Hemophilia B; Hepatitis C Virus (HCV); Hepatitis virus B (HBV); Human immune deficiency Virus (HIV)

Indexed keywords

EID: 73949122255     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2009.2777     Document Type: Article

References (48)

1. Goedert J.J., Eyster M.E., Lederman M.M., et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100 (5): 1584-1589.
2. Sharara A.I., Hunt M.Ch., Hamilton J.D. Hepatitis C. Ann. Intern. Med. 1996; 125(8): 658-668.
3. Makris M., Garson J.A., Ring C.J.A., et al. Hepatitis C viral RNA in Clotting Factor Concentrates and the Development of Hepatitis in Recipients. Blood. 1993; 81(7): 1898-1902.
4. Yee T.T., Griffioen A., Sabin C.A., et al. The natyral history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut. 2000; (47): 845-851.
5. Mannucci P.M., Gdovin S., Gringeri A., et al. Transmission of hepatitis A to patients with haemophilia by factor VIII Concentrates treated with organic Solvent and detergent to inactivate Viruses. Ann. Intern. Med. 1994; 120(1): 1-7.
6. Rumi M.G., Colombo M., Romeo R., et al. Serum hepatitis B Virus DNA detects cryptic hepatits B virus infections in multitrans-fused hemophilic patients. Blood. 1990; 75(8): 1654-1658.
7. Brettler D.B., Alter H.J., Dienstag J.L., et al. Prevalence of hepatitis C virus antibody in a cohort haemophilia patients. Blood. 1990; 76(1): 254-256.
8. Giangrande P. L.F. Hepatitis in Haemophilia. Review. Br. J. Hae-matol. 1998; 103:1-9.
9. Blanchette V.S., Vorstman E., Shore A., et al. Hepatitis C infection in children with Hemophilia A and B. Blood. 1991; 78(2): 285-289.
10. Franchini M., Rossetti G., Tagliaferri A., et al. The natyral history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood. 2001; 98(6) : 1836-1841.
11. Tong M.J., El-Farra N.S., Reikes A.R., et al. Clinical Outcomes after Transfusion-Associated Hepatitis. N. Engl. J. Med. 1995; 332(22): 1463-1466.
12. Roberts H.R., Hoffman M. Hemophilia A and Hemophilia B In: Beutler E., Lichtman M.A., Coller B.S., et al., editors, Willams He-matology. New York Mc Graw-Hill. 2000; pp/1639-1658.
13. Laursen A.L., Scheibel E., Ingerslev J., et al. Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Haemophilia. 1998; 4: 25-32.
14. Rumi M.G., Santagostino E., Morfini M., et al. A multicenter Controlled Randomized Open Trial of Interferon alfa- 2b Treatment of Anti-Human Immunodeficiency Virus-Negative Hemophilic Patients With Chronic Hepatitis C. Blood. 1997; 89(10): 3529-3533.
15. Santagostino E., Rumi G.M., Rivi M., et al. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood. 2002; 99(3): 1089-1091.
16. Posthouwer D., Wolters V.M., Fischer K., et al. Hepatitis C infection in children with haemophilia: a pilot study. Haemophilia. 2004; 10: 722-726.
17. Rumi M.G., De Filippi F., Santagostino E., et al. Hepatitis C in Haemophilia: lights and shadows. Haemophilia. 2004; 10(4): 211-215.
18. Tradati F., Colombo M., Manucci P.M., et al. A Prospective Mul-ticenter Study of Hepatocellular Carcinoma in Italian Hemophiliacs With Chronic Hepatitis C. Blood. 1998; 91(4): 1173-1177.
19. Kasper C.K. Hereditary plasma clotting factor disorders and their management. Haemophilia. 2000; 6(1):13-27.
20. Carneiro-Proietti A.B.F., Lima-Martins M.V.C., Passos V.M.A., et al. Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II(HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results. Haemophilia. 1998; : 47-50.
21. Evan Sadler J., Davie E.W. Hemophilia A, Hemophilia B, and von Willebrand Disease In:Stamatoyannopoulos G., Majerus P.W, Perlmutter R.M. et al.,editors, The Molecular Basis of Blood Dis-eases.Philadelphia:W.B Saunders Company 2001; pp.: 680-697.
22. Montoro J.B., Oliveras J., Ignacio Lorenzo J., et al. An association Between Clotting Factor Concentrates Use and Mortality in Human Immunodeficiency Virus-Infected Hemophilic Patients. Blood. 1995; 86(6): 2213-2219.
23. Astermark J., Johnsson H., Stigendal L., et al. HIV-disease progression in Swedish haemophiliacs and the influence of replacement therapy. Haemophilia. 1997 3: 277-282.
24. Mannucci P.M. Hemophilia and related bleeding disorders. A story of dismay and success. Hematology. 2002:1-7.
25. Bray G.L., Gomperts E.D., Courter S., et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994; 83: 2428-2435.
26. Lusher J.M., Arkin S., Abildgaard C.F., et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N. Engl. J. Med. 1993; 328(7): 453-459.
27. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999; 5(4): 253-259.
28. Triemstra M., Rosendaal F.R., Smit C., et al. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann. Intern. Med. 1995; 123(111:823-830.
29. Valentino I.A., Ewenstein B., Navickis R.J., et al. Central venous access devices in haemophilia. Haemophilia. 2004; 10: 134-146.
30. Chuansumrit A., Krasaesub S., Angchaisuksiri P., et al. Survival analysis of patients with haemophilia at the Intrnational Haemophilia Training Centre, Bangkok, Thailand. Haemophilia. 2004; 10: 542-549.
31. Ghosh K., Shetty S., Kulkarni B., et al. Development of inhibitors in patients with haemophilia from India. Haemophilia. 2001; 7: 273-278.
32. Evensen S.A., Ulstrup J., Skaug K., et al. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in haemophiliacs treated with lyophilize cryoprecipitate from volunteer donors. Eur J Haematol. 1987; 39(1): 44-48.
33. Yamada-Osaki M., Sumazaki R., Kajiwara Y., et al. Natural course of HGV infection in haemophiliacs. Br. J. Haematol. 1988;102:616-621.
34. Ludlam C.A., Lee R.J., Prescott R.J., et al. Haemophilia care in central Scotland 1980-1994. I. Demographic characteristics, hospital admission and causes of death. Haemophilia. 2000; 6: 494-503.
35. Bauduer F., Degioanni A., Ducout L., et al. Distribution of haemophilia in the French Basque Country. Haemophilia. 2002; 8: 735-739.
36. Yokozaki Sh., Takamatsu J., Nakano I., et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood. 2000; 96(13): 4293-4299.
37. Globe D.R., Curtis R.G., Koerper M.A. Utilization of care in haemophilia: a resource-based method for coast analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10(1): 63-70.
38. Goedert J.J, Brown D.L., Hoots K., et al. Human immunodeficiency and hepatits virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia. 2004; 10(4): 205-210.
39. Brettler D.B., Alter H.J., Dienstag J.L., et al. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood. 1990; 76(1): 254-256.
40. Maisonneuve P., Laurian Y., Guerois C., et al. Antibody to hepatitis C (anti C 100-3) in French hemophiliacs. Nouv. Rev. Fr. He-matol. 1991; 33(3): 263-266.
41. Makris M., Preston F.E., Triger D.R., et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet. 1990; 12;335(8698): 1117-1119.
42. Mauser-Bunschoten E.P., Damen M., Reesink H.W., et al. Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C. Ann. Intern. Med. 1996; 125(4): 297-299.
43. Foster Pr., Mcintosh R.V., Macleod A.J. Hepatitis C and haemophilia. BMJ. 1995; 311(7007): 754-755.
44. Martinez-Murillo C., Quintana S., Ambriz R., et al. An economic model of Haemophilia in Mexico. Haemophilia. 2004; 10: 9-17.
45. Peerlinck K., Rosendaal F.R., Vermylen J. Incidence of inhibitor development in a Group of Young Hemophilia A patients treated exclusively with Lyophilized cryoprecipitate. Blood. 1993; 81(12): 3332-3335.
46. Gringeri A., Von Mackensen S., Auerswald G., et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia. 2004; 10(1): 26-33.
47. Kavakli K., Gringeri A., Bader R., et al. Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia. 1998; 4: 106-108.
48. Takayama S., Taki M., Meguro T., et al. Virological Characteristics of HCV infection in Japanese haemophiliacs. Haemophilia. 1997; 3: 131-136. (Pubitemid 27187179)